[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Urogen Pharma Ltd (URGN)

Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,948,880
  • Shares Outstanding, K 48,722
  • Annual Sales, $ 109,790 K
  • Annual Income, $ -153,490 K
  • EBIT $ -108 M
  • EBITDA $ -110 M
  • 60-Month Beta 1.56
  • Price/Sales 17.66
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 97.17% (+12.33%)
  • Historical Volatility 37.02%
  • IV Percentile 75%
  • IV Rank 28.10%
  • IV High 188.55% on 03/20/26
  • IV Low 61.45% on 08/26/25
  • Expected Move (DTE 35) 4.34 (10.78%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 340
  • Volume Avg (30-Day) 395
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 6,997
  • Open Int (30-Day) 6,534
  • Expected Range 35.87 to 44.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.38
  • Number of Estimates 3
  • High Estimate $-0.25
  • Low Estimate $-0.61
  • Prior Year $-1.05
  • Growth Rate Est. (year over year) +63.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.21 +24.60%
on 06/18/26
41.88 -4.17%
on 07/17/26
+7.32 (+22.33%)
since 06/17/26
3-Month
22.07 +81.85%
on 04/20/26
41.88 -4.17%
on 07/17/26
+17.59 (+78.06%)
since 04/17/26
52-Week
14.89 +169.54%
on 07/18/25
41.88 -4.17%
on 07/17/26
+24.72 (+160.45%)
since 07/17/25

Most Recent Stories

More News
Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027

UroGen Pharma (URGN) has surged nearly 180% over the past year and has strong technical momentum. URGN maintains a 100% “Buy” technical opinion from Barchart. The company’s revenue is projected to...

URGN : 40.30 (+0.75%)
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

PRINCETON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 40.30 (+0.75%)
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026 UGN-501 is a differentiated...

URGN : 40.30 (+0.75%)
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 40.30 (+0.75%)
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

Agreement reinforces the value of UroGen’s innovation and reflects the strength of the Company’s intellectual property portfolio Teva will be granted a non-exclusive license to sell its generic...

URGN : 40.30 (+0.75%)
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced...

URGN : 40.30 (+0.75%)
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced...

URGN : 40.30 (+0.75%)
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three Months First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk...

URGN : 40.30 (+0.75%)
UroGen Pharma to Present at Upcoming Investor Conferences

PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty...

URGN : 40.30 (+0.75%)
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026 JELMYTO achieved...

URGN : 40.30 (+0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen...

See More

Key Turning Points

3rd Resistance Point 42.88
2nd Resistance Point 42.12
1st Resistance Point 41.06
Last Price 40.30
1st Support Level 39.24
2nd Support Level 38.48
3rd Support Level 37.42

See More

52-Week High 41.88
Last Price 40.30
Fibonacci 61.8% 31.57
Fibonacci 50% 28.39
Fibonacci 38.2% 25.20
52-Week Low 14.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.